
Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma
Three years ago, Harvard’s Doug Melton published a landmark study outlining how he had successfully used stem cells to create insulin-producing pancreatic beta cells that were inserted in bulk into mice and successfully protected from an immune response — a breakthrough in regenerative medicine that bore real promise to provide a curative approach for Type 1 diabetes that could conceivably end a lifetime of insulin shots.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.